1. Volume 355, Issue 9212, Pages 1295-1302 (April 2000)
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial 
The Lancet 
Volume 355, Issue 9212, Pages (April 2000)
DOI: /S (00)
Copyright © 2000 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

3. Figure 2
Proportional effects of aspirin on pulmonary embolism and symptomatic deep-vein thrombosis after hip fracture
Black squares=point estimates (with area proportional to number of events) and horizontal lines=95% CI for observed effects in different subgroups. Diamonds=point estimates and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line=hazard ratio of 1·0 (ie, no effect of treatment), and dotted vertical line=observed overall effect. Any venous thromboembolism refers to numbers of patients with deep-vein thrombosis, pulmonary embolism, or both (ie, avoids double-counting of any patients with more than one such event).
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

4. Figure 3
Absolute effects of aspirin on pulmoary embolism and deep-vein thrombosis after hip fracture
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

5. Figure 4
Proportional effects of aspirin on pulmonary embolism and symptomatic deep-vein thrombosis in various subgroups of hip-fracture patients.
Conventions as in figure 2. UF=unfractionated standard heparin; LMW=low-molecular-weight heparin. Denominators for subgroups defined by week of follow-up (open squares) are all patients alive at start of each follow-up period.
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions

6. Figure 5
Proportional effects of antiplatelet therapy on venous thromboembolism in previous meta-analysis and PEP trial
*Only symptomatic deep-vein thrombosis recorded in PEP trial. Conventions as in Figure 2. Reference 17 provided results for previous meta-analysis. In most trials in that meta-analysis, patients were roughly evenly assigned antiplatelet therapy or control, but in some, more were deliberately assigned to active treatment. To allow direct comparisons of percentages observed to have an event in each treatment group, adjusted totals were given after converting any uneven randomised trials to even ones by counting the control groups more than once. Statistical calculations were, however, based on stratified analyses of actual numbers from individual trials (unadjusted controls in previous meta-analysis: 761/2316 for deep-vein thrombosis and 117/4216 for pulmonary embolism).
The Lancet  , DOI: ( /S (00) )
Copyright © 2000 Elsevier Ltd Terms and Conditions